Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Dovish Draghi Sparks Off Rally Across Europe

Tue, 18th Jun 2019 16:59

(Alliance News) - An unremarkable start to the day for London stocks picked up mid-morning as dovish comments from European Central Bank President Mario Draghi boosted equities across Europe. "The Italian - who is in the endgame of his tenure at the top of the central bank - claimed both cutting interest rates and boosting its asset purchase program remain part of the ECB's tool set, comments that immediately turned a potentially fretful session into one full of triple-digit growth," observed Connor Campbell at Spreadex. Also contributing to the FTSE 100's gains on Tuesday were a well-received set of annual results from equipment rental firm Ashtead, and positive regulatory news for drugmaker AstraZeneca.The FTSE 100 index closed up 85.73 points, or 1.2%, at 7,443.04. The FTSE 250 ended up 154.18 points, or 0.8%, at 19,311.79, and the AIM All-Share closed up 0.98 of a point, or 0.1%, at 938.44.The Cboe UK 100 ended up 1.3% at 12,643.11, the Cboe UK 250 closed up 0.8% at 17,311.46, and the Cboe Small Companies ended flat at 11,643.76.ECB chief Draghi, speaking in Portugal, opened up the possibility of more stimulus measures should the economic outlook not improve and inflation not pick up in the eurozone."In the absence of improvement, such that the sustained return of inflation to our aim is threatened, additional stimulus will be required," Draghi said Tuesday at a speech at the annual ECB Forum on Central Banking in Sintra."And the APP [asset purchase programme] still has considerable headroom," he added, noting that risks to the euro area economic outlook remain tilted to the downside.US President Donald Trump, who last week complained that the European single currency is unfairly valued against the greenback, used Draghi's latest comments as a chance to slam the ECB's loose monetary policy."Mario Draghi just announced more stimulus could come, which immediately dropped the Euro against the Dollar, making it unfairly easier for them to compete against the USA," Trump tweeted.The euro stood at USD1.1193 at the European equities close Tuesday, down from USD1.1233 at the same time on Monday.Following the Sintra comments, Danske Bank said it expects the ECB to begin preparing markets for looser policy as soon as next month."We expect ECB to include 'at present or lower' levels in the July meeting, but only cut rates in September as part of a package together with restart of QE," said Danske Bank.The bank continued: "As the Sintra piece entails a sense of urgency and bold statements, we expect a 20 basis point cut in the deposit rate and the MRO rate and 25bp in the lending rate, to the new rates being negative 60bp, negative 20bp and 0% respectively."In European equities on Tuesday, the CAC 40 in Paris ended up 2.3%, while the DAX 30 in Frankfurt advanced 2.2%."Draghi's comments come just as the Fed start their two-day monetary policy meeting today and investors are starting to position themselves for a more dovish statement. Whilst a rate cut is not broadly expected today, market players believe that the Fed will start to adjust the statement to signal a rate cut either as soon as July, if not September," said Fiona Cincotta at City Index.Stocks in New York were higher at the London equities close, with the Dow Jones up 1.4%, the S&P 500 index rising 1.3%, and the Nasdaq Composite climbing 1.9%.Trump is planning an "extended meeting" with China's President Xi Jinping on the sidelines of the G20 summit in Japan at the end of June, the US President tweeted.Washington and Beijing have been locked in a trade war for months, with the US government imposing new tariffs on around half of all Chinese imports. Trump has threatened to extend these measures to all imports from China, and Beijing has threatened retaliatory measures.Trump said he had a "very good" conversation with Xi on the phone and that Washington and Beijing would start talks ahead of the summit.In the UK, the pound was quoted at USD1.2551 at the London equities close Tuesday, soft compared to USD1.2559 at the close on Monday.Conservative MPs are taking part in a second round of voting to narrow down the list of candidates standing to be new party leader and UK prime minister.Tory MPs will vote in the second bout of the contest to select Britain's next prime minister on Tuesday ahead of a live TV debate that will feature front-runner and former foreign secretary Boris Johnson.Candidates need to gain at least 33 votes from MPs to remain in the race to reach the final run-off, which will see some 160,000 Tory members select the next prime minister.If all candidates pass the 33-vote threshold, the one with the lowest total will be eliminated and by the end of the week, four of the six current riders will be forced out, leaving the final two to go head-to-head for votes from the Tory grassroots.The ongoing leadership contest comes as a poll has suggested most Conservative party members would be prepared to sacrifice the union, destroy their party, or suffer economic damage to get the UK out of the EU.The YouGov survey found that 63% of members would be prepared to see Brexit take place even if it meant Scotland leaving the UK. Some 61% would rather Brexit took place even if it caused "significant damage" to the economy, 59% would prioritise leaving the EU even if it meant Northern Ireland breaking away from the rest of the UK, and 54% would accept the Tory party "being destroyed" in order to secure Brexit.In commodities, Brent oil was quoted at USD62.56 a barrel at the London equities close Tuesday, up from from USD61.66 late Monday."Throughout 2019, there has been a largely positive correlation between oil and equities, and that is playing out today. The perception that US-China relations might improve is helping the oil market," said David Madden at CMC Markets. This caused London-listed BP to gain 2.1% and Royal Dutch Shell 'A' and 'B' shares to advance 1.4% and 1.5% respectively. Gold, meanwhile, was quoted at USD1,347.87 an ounce at the London equities close Tuesday against USD1,340.19 at the close on Monday.Back in the FTSE 100, Ashtead ended as the best blue-chip performer, up 5.7% after revealing a GBP500 million share buyback alongside a strong set of annual results. For the year to April 30, Ashtead recorded pretax profit of GBP1.06 billion, up 23% from GBP862.1 million the year before, as revenue increased 19% to GBP4.50 billion.Underlying pretax profit was up 17% to GBP1.11 billion, in line with consensus, while rental revenue was up 18% to GBP4.14 billion.Ashtead, which rents out construction and industrial equipment, said its core Sunbelt US division recorded revenue of GBP3.82 billion for the 2019 financial year versus GBP3.10 billion the year before.Drugmaker AstraZeneca advanced 2.5% after getting European approval for Lynparza in ovarian cancer.The European Commission approved the drug for adults patients with stage three and four ovarian cancer who have a BRCA mutation. BRCA1 and BRCA2 genes help suppress the growth of tumours, and mutations in these genes is associated with an increased risk of cancer.Lynparza is part of a strategic oncology collaboration between Astra and US pharma company Merck & Co, and the two companies are pursuing further ovarian cancer trials, including an ongoing trial of Lynparza in combination with bevacizumab. This is the third indication for Lynparza in the EU.International Consolidated Airlines shares ended up 1.2% after signing a deal to purchase 200 Boeing B737 short to medium-range aircraft for its fleet with deliveries set to begin in 2023.Additionally, IAG has ordered eight Airbus A321XLR aircraft for its Iberia fleet and six for Aer Lingus airline, plus 14 options.The letter of intent with Boeing - which remains subject to formal agreement - would see IAG take delivery of a mix of 737-8 and 737-10 between 2023 and 2027. The planes would be powered by the CFM Leap engines.In a separate announcement, Boeing confirmed the planes are from the troubled MAX series of the aircraft. Earlier in 2019, the 737 MAX version of the aircraft was grounded following two fatal crashes involving the plane.Boeing - with shares up 2.4% in New York - added that the deal with IAG is worth more than USD24 billion at list prices. At the bottom of the index was Premier Inn hotel owner Whitbread, down 1.3%, as the firm prepares to report first quarter results on Wednesday.Russian steelmaker Evraz ended down 2.3% after Citigroup cut the stock to Sell from Neutral.In the FTSE 250, Kier rebounded 9.4% after shedding 17% in the previous session after suspending its dividend and putting several businesses up for sale in order to control debt.In the UK corporate calendar on Wednesday, housebuilder Berkeley releases annual results alongside full-year figures from luxury bag maker Mulberry. Over-50s insurer Saga releases a trading statement. In the economic calendar on Wednesday, Japanese imports and exports for May are at 0050 BST and German produce prices are at 0700 BST, followed by the eurozone current account at 0900 BST. In the UK, produce and consumer prices are due out at 0930 BST and eurozone construction output at 1000 BST. In the US, the two-day meeting of the Federal Open Market Committee concludes with a policy decision due at 1900 BST and a press conference with Chair Jerome Powell at 1930 BST.London Close is available to subscribers as an email newsletter. Contact info@alliancenews.com

More News
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.